Quick answer
A team at Union Hospital in Wuhan reported the longest follow-up to date of an in-vivo CAR-T therapy for relapsed or refractory multiple myeloma — a blood cancer. Of four patients who received a single infusion, one remained in strict complete remission 15 months later, and all four responded at first [1][3]. The approach edits a patient's own immune cells inside the body, so it skips the cell-collection and chemotherapy preparation that make conventional CAR-T slow and costly [2].
Key takeaways
- All four patients responded; two reached strict complete remission and two partial remission in the first report [2].
- In the longer follow-up, one patient — the one with the lowest tumour burden at the start — was still in strict complete remission at 15 months; median progression-free survival was 4 months [1][3].
- No leukapheresis (cell collection) and no lymphodepletion (pre-treatment chemotherapy) were used — the CAR gene is delivered directly into the body by a lentiviral vector [1][2].
- Safety events were expected for CAR-T: cytokine release syndrome (grades 1–3) and low blood counts (grade ≥3) in everyone, plus one mild neurological event [1][3].
- This is early, four-patient evidence; it is not a cure and not an available treatment for visitors [1][3].
The condition in context: multiple myeloma
Multiple myeloma is a cancer of plasma cells — the antibody factories of the bone marrow. It is the second most common blood cancer after lymphoma, mostly affects older adults, and is still considered incurable: treatment controls it but it usually returns [7]. That is why new formats of cell therapy matter.
| Region | What the data shows | Source |
|---|---|---|
| Worldwide | About 188,000 new cases and 121,000 deaths from multiple myeloma in 2022 — and the numbers are projected to rise with ageing populations [4]. | GLOBOCAN 2022 / IARC [4] |
| China | An estimated 17,000 new cases and 13,000 deaths a year (2021), with an incidence of roughly 2.5–4.0 per 100,000 — lower than in North America or Western Europe but climbing as the population ages [4][7]. | GLOBOCAN / national registries [4] |
| United States | About 36,000 new cases and 10,850 deaths expected in 2026; lifetime risk is about 1 in 108 for men and 1 in 133 for women, and 5-year survival is about 64% [5]. | American Cancer Society 2026 [5] |
| Europe | Incidence is about 4.5–6.0 per 100,000 people per year — among the higher rates in the world [6]. | EHA–ESMO guidance [6] |
| Southeast Asia | Incidence and mortality are lower than in high-income regions but are rising as populations age, with care access uneven across the 11 countries [7]. | JCO Global Oncology 2025 [7] |
The figures mix incidence (new cases) and deaths and are rounded; they show how common and how serious the disease is, not a like-for-like league table [4][5][6][7].
What happened
The work was led by Mei Heng and Hu Yu at Union Hospital, part of Tongji Medical College, Huazhong University of Science and Technology, and published in Nature Medicine on 6 October 2026 [1]. The therapy, called ESO-T01, targets BCMA — a protein that sits on myeloma cells — and is delivered by a lentiviral vector, a harmless virus modified to carry the CAR gene into the patient's own T cells [1][2].
Conventional CAR-T is made ex vivo: blood is drawn, the T cells are separated out, re-engineered in a lab and expanded, then infused back weeks later — a process that is slow and can cost hundreds of thousands of dollars [2]. The Wuhan team's in-vivo version delivers the gene directly, so there is no cell collection and no lymphodepletion — the chemotherapy given first to make room for the new cells [1][2]. In the first report, all four patients responded; the new paper follows them longer and documents safety, immune response, and where the virus landed in the genome [1][3].
One reason this matters is access. A U.S. real-world study of patients listed for commercial BCMA CAR-T found that fewer than 40% actually received it within 12 months, and 26% died while waiting [3]. A therapy that needs no manufacturing could, in principle, reach more people and faster.
The case as reported
The clearest individual result was one patient — the one whose tumour burden was lowest at the start — who was still in strict complete remission 15 months after the single infusion [1][3]. The other three eventually relapsed, with survival from infusion of 5.5 to 10.9 months, a reminder that the effect was not uniform [1][3]. The team described the long-term responder's CAR-T cells as persisting and re-expanding, which they suggest is why the remission held [1].
Why it matters
| For the patient | What the trial suggests | Source |
|---|---|---|
| Access and wait time | No manufacturing means, in principle, a same-week therapy instead of a weeks-long wait [2][3]. | [2][3] |
| Cost | Removing bespoke cell production is the main way in-vivo CAR-T could become far cheaper [2]. | [2] |
| Safety | The side effects were those already known for CAR-T and were manageable in this small group [1][3]. | [1][3] |
The trial also established a 'Union protocol' for monitoring this new format — tracking how the engineered cells behave, whether the body makes antibodies against them, and where the virus integrates — which the team argues is needed before larger studies [1].
Availability and limits
- Only four patients were treated; this is early, not proof of benefit at scale [1][3].
- Median progression-free survival was 4 months — the remissions did not all last, and durability is the key open question [1][3].
- It remains a research therapy in China; it is not an approved or available treatment for foreign visitors [1].
- The waiting-list mortality and cost figures come from U.S. data, not from this trial, and may not apply in China [3][5].
What to ask before booking
| Question | Why it matters |
|---|---|
| Does the hospital run CAR-T for myeloma, and in what setting — trial or approved therapy? | Determines whether you could actually be treated or only screened. |
| Am I eligible for a clinical trial, and what would it cost? | In-vivo CAR-T is still investigational; trials, not open bookings, are where it lives [1]. |
| Who would coordinate my care in my language? | Cell therapy involves many steps; language support affects safety. |
| What is my home specialist's view on travelling for experimental therapy? | Myeloma management is continuous; your own team should stay involved. |
Questions patients ask
What is CAR-T therapy, in plain terms?
CAR-T stands for chimeric antigen receptor T-cell therapy. A patient's T cells — the immune cells that normally hunt threats — are given a new receptor that lets them recognise and attack cancer cells. In the usual form, the cells are taken out, re-engineered and returned. In this trial, the re-engineering happened inside the body [2].
What does 'in vivo' mean, and why does it matter?
'In vivo' means 'in the living body'. Here it means the CAR gene is delivered directly into the patient's T cells with a harmless virus, instead of being built in a lab. That removes the cell-collection step and the preparatory chemotherapy, which are the main reasons conventional CAR-T is slow and expensive [1][2].
Is this a cure for multiple myeloma?
No. All four patients responded at first, but three later relapsed and median progression-free survival was 4 months. One patient's remission lasted 15 months. The trial shows the approach can work and is safe enough to study further, not that it cures the disease [1][3].
Could a foreign patient get this treatment in China?
Not yet. It is an investigational therapy described in a research paper, not an open international service, and the hospital has not published a pathway for overseas patients [1]. If you are considering myeloma care in China, discuss trials and approved options with the hospital's international department.
How is this different from CAR-T already used in the West?
Western-approved CAR-T for myeloma is made outside the body and can involve weeks of waiting and high cost; a U.S. study found many listed patients never received it in time [3]. In-vivo CAR-T aims to skip manufacturing entirely, which is why access — not just efficacy — is the headline [2][3].